Prostate cancer cases likely to double by 2040, finds study

The findings of a new study on one of the most common types of cancer seen worldwide are alarming. The study published in the Lancet has found that the number of new prostate cancer cases around the world will more than double over the next two decades. "Our findings suggest that the number of new cases annually will rise from 1.4 million in 2020 to 2.9 million by 2040," said the medical journal, based on a study of demographic changes.

It is a big concern right now because prostate cancer accounts for about 15 per cent of the total cases of cancer seen in men.

Prostate cancer is a malignancy that develops in the prostate gland, a walnut-sized organ located below the bladder and in front of the rectum in men. It occurs when cells in the prostate gland mutate and grow uncontrollably, forming tumors. Prostate cancer is one of the most common cancers in men, particularly in older age groups.

Several factors are responsible for driving the surge in prostate cancer. Prostate cancer risk factors include age, with the risk increasing significantly after the age of 50. Family history and genetics play a role, as men with close relatives diagnosed with prostate cancer have a higher risk. Ethnicity also influences risk, with African-American men having a higher likelihood of developing prostate cancer compared to other ethnic groups. Lifestyle factors such as a diet high in red meat and low in fruits and vegetables, obesity, and lack of physical activity may also increase the risk. Exposure to certain environmental factors and inflammation of the prostate gland may contribute to the development of prostate cancer.


Early signs of prostate cancer may include changes in urinary habits such as frequent urination, difficulty starting or stopping urination, weak urine flow, or the presence of blood in the urine or semen. Some men may experience erectile dysfunction or discomfort in the pelvic area. However, it's important to note that early-stage prostate cancer often presents with no symptoms at all. Regular screening tests, such as prostate-specific antigen (PSA) blood tests and digital rectal exams (DRE), are crucial for detecting prostate cancer in its early stages when treatment is most effective. Any concerning symptoms should prompt a visit to a healthcare professional for evaluation.